

Propensity score matching

Overall population (n=10810)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1012)

3–5 mmol/mol (n=1262)

0–3 mmol/mol (n=3380)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=2988)

3–5 mmol/mol (n=1368)

>5 mmol/mol (n=800)

Average treatment effect



Propensity score matching + adjust

Overall population (n=10810)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1012)

3–5 mmol/mol (n=1262)

0–3 mmol/mol (n=3380)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=2988)

3–5 mmol/mol (n=1368)

>5 mmol/mol (n=800)

Average treatment effect



Adjust

Overall population (n=28685)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=2193)

3–5 mmol/mol (n=2853)

0–3 mmol/mol (n=8741)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=9064)

3–5 mmol/mol (n=3778)

>5 mmol/mol (n=2056)


Average treatment effect



Propensity score matching

SGLT2 GLP1


Overall population (n=16280)



Propensity score matching + adjusted

SGLT2 GLP1


Overall population (n=16280)



Adjusted

SGLT2 GLP1

Overall population (n=41728)




eGFR change

Propensity score matching

SGLT2 GLP1


Overall population (n=16618)



Propensity score matching + adjusted

SGLT2 GLP1


Overall population (n=16618)



Adjusted

SGLT2 GLP1


Overall population (n=44339)



Propensity score matching

SGLT2 GLP1


Overall population (n=30992)



Propensity score matching + adjusted

SGLT2 GLP1


Overall population (n=30992)



Adjusted


SGLT2 GLP1

Overall population (n=77741)




Propensity score matching

Overall population (n=17094)




Propensity score matching + adjusted

Overall population (n=17094)



Adjusted

Overall population (n=52052)



Propensity score matching

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 19)

3–5 mmol/mol (n=2069, event = 20)

0–3 mmol/mol (n=5420, event = 79)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4729, event = 81)

3–5 mmol/mol (n=2079, event = 33)

>5 mmol/mol (n=976, event = 30)

Average treatment effect



Propensity score matching + adjusted

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 19)

3–5 mmol/mol (n=2069, event = 20)

0–3 mmol/mol (n=5420, event = 79)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4729, event = 81)

3–5 mmol/mol (n=2079, event = 33)

>5 mmol/mol (n=976, event = 30)

Average treatment effect



Adjusted

Overall population (n=52052)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4236, event = 42)

3–5 mmol/mol (n=5327, event = 43)

0–3 mmol/mol (n=16279, event = 185)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=16419, event = 208)

3–5 mmol/mol (n=6763, event = 94)

>5 mmol/mol (n=3028, event = 83)

Average treatment effect



– stage 3/4/5 outcomes for no CVD/HF/CKD population (GLP1 control, values correspond to SGLT2i)

Propensity score matching

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 11)

3–5 mmol/mol (n=2069, event = 13)

0–3 mmol/mol (n=5420, event = 67)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4729, event = 111)

3–5 mmol/mol (n=2079, event = 60)

>5 mmol/mol (n=976, event = 59)

Average treatment effect



Propensity score matching + adjusted

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 11)

3–5 mmol/mol (n=2069, event = 13)

0–3 mmol/mol (n=5420, event = 67)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4729, event = 111)

3–5 mmol/mol (n=2079, event = 60)

>5 mmol/mol (n=976, event = 59)

Average treatment effect



Adjusted

Overall population (n=52052)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4236, event = 24)

3–5 mmol/mol (n=5327, event = 22)

0–3 mmol/mol (n=16279, event = 117)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=16419, event = 239)

3–5 mmol/mol (n=6763, event = 145)

>5 mmol/mol (n=3028, event = 152)

Average treatment effect



Propensity score matching

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 6)

3–5 mmol/mol (n=2069, event = 9)

0–3 mmol/mol (n=5420, event = 20)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4729, event = 29)

3–5 mmol/mol (n=2079, event = 19)

>5 mmol/mol (n=976, event = 9)

Average treatment effect



Propensity score matching + adjusted

Overall population (n=17094)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1821, event = 6)

3–5 mmol/mol (n=2069, event = 9)

0–3 mmol/mol (n=5420, event = 20)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4729, event = 29)

3–5 mmol/mol (n=2079, event = 19)

>5 mmol/mol (n=976, event = 9)

Average treatment effect



Adjusted

Overall population (n=52052)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4236, event = 13)

3–5 mmol/mol (n=5327, event = 13)

0–3 mmol/mol (n=16279, event = 42)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=16419, event = 53)

3–5 mmol/mol (n=6763, event = 36)

>5 mmol/mol (n=3028, event = 28)

Average treatment effect



Propensity score matching

Overall population (n=18554)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1874, event = 21)

3–5 mmol/mol (n=2102, event = 13)

0–3 mmol/mol (n=5564, event = 61)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=5154, event = 68)

3–5 mmol/mol (n=2347, event = 24)

>5 mmol/mol (n=1513, event = 32)

Average treatment effect



Propensity score matching + adjusted

Overall population (n=18554)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1874, event = 21)

3–5 mmol/mol (n=2102, event = 13)

0–3 mmol/mol (n=5564, event = 61)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=5154, event = 68)

3–5 mmol/mol (n=2347, event = 24)

>5 mmol/mol (n=1513, event = 32)

Average treatment effect



Adjusted

Overall population (n=54852)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4320, event = 43)

3–5 mmol/mol (n=5406, event = 41)

0–3 mmol/mol (n=16634, event = 173)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=17142, event = 198)

3–5 mmol/mol (n=7248, event = 79)

>5 mmol/mol (n=4102, event = 71)

Average treatment effect



Propensity score matching

Overall population (n=22842)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=2074, event = 7)

3–5 mmol/mol (n=2458, event = 10)

0–3 mmol/mol (n=6733, event = 37)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=6524, event = 37)

3–5 mmol/mol (n=3021, event = 22)

>5 mmol/mol (n=2032, event = 31)

Average treatment effect



Propensity score matching + adjusted

Overall population (n=22842)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=2074, event = 7)

3–5 mmol/mol (n=2458, event = 10)

0–3 mmol/mol (n=6733, event = 37)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=6524, event = 37)

3–5 mmol/mol (n=3021, event = 22)

>5 mmol/mol (n=2032, event = 31)

Average treatment effect



Adjusted

Overall population (n=66428)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=4765, event = 11)

3–5 mmol/mol (n=6188, event = 17)

0–3 mmol/mol (n=19413, event = 62)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=21327, event = 81)

3–5 mmol/mol (n=9219, event = 45)

>5 mmol/mol (n=5516, event = 63)

Average treatment effect



Propensity score matching

Overall population (n=11634)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1360, event = 249)

3–5 mmol/mol (n=1404, event = 262)

0–3 mmol/mol (n=3537, event = 625)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=3330, event = 530)

3–5 mmol/mol (n=1495, event = 220)

>5 mmol/mol (n=508, event = 79)

Average treatment effect



Propensity score matching + adjusted

Overall population (n=11634)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1360, event = 249)

3–5 mmol/mol (n=1404, event = 262)

0–3 mmol/mol (n=3537, event = 625)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=3330, event = 530)

3–5 mmol/mol (n=1495, event = 220)

>5 mmol/mol (n=508, event = 79)

Average treatment effect



Adjusted

Overall population (n=34524)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=3098, event = 561)

3–5 mmol/mol (n=3498, event = 598)

0–3 mmol/mol (n=10288, event = 1655)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=11328, event = 1567)

3–5 mmol/mol (n=4765, event = 620)

>5 mmol/mol (n=1547, event = 227)

Average treatment effect



Propensity score matching

Overall population (n=15496)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1688, event = 262)

3–5 mmol/mol (n=1848, event = 250)

0–3 mmol/mol (n=4602, event = 536)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4354, event = 455)

3–5 mmol/mol (n=2002, event = 178)

>5 mmol/mol (n=1002, event = 107)

Average treatment effect



Propensity score matching + adjusted

Overall population (n=15496)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=1688, event = 262)

3–5 mmol/mol (n=1848, event = 250)

0–3 mmol/mol (n=4602, event = 536)


Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=4354, event = 455)

3–5 mmol/mol (n=2002, event = 178)

>5 mmol/mol (n=1002, event = 107)

Average treatment effect



Adjusted

Overall population (n=43922)

Predicted HbA1c benefit on SGLT2i

>5 mmol/mol (n=3647, event = 537)

3–5 mmol/mol (n=4542, event = 593)

0–3 mmol/mol (n=12866, event = 1513)

Predicted HbA1c benefit on GLP1–RA

0–3 mmol/mol (n=14101, event = 1374)

3–5 mmol/mol (n=6092, event = 528)

>5 mmol/mol (n=2674, event = 270)

Average treatment effect

